Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 445

1.

Cytoplasmic dsRNA induces the expression of OCT3/4 and NANOG mRNAs in differentiated human cells.

Wang G, Kouwaki T, Mugikura K, Okamoto M, Takaki H, Funami K, Seya T, Oshiumi H.

J Biol Chem. 2019 Oct 15. pii: jbc.RA119.009783. doi: 10.1074/jbc.RA119.009783. [Epub ahead of print]

2.

A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.

Seya T, Takeda Y, Matsumoto M.

Adv Drug Deliv Rev. 2019 Jul 11. pii: S0169-409X(19)30118-8. doi: 10.1016/j.addr.2019.07.008. [Epub ahead of print]

PMID:
31302192
3.

Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy.

Yoshida S, Shime H, Matsumoto M, Kasahara M, Seya T.

Front Immunol. 2019 Apr 4;10:671. doi: 10.3389/fimmu.2019.00671. eCollection 2019.

4.

Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.

Takeda Y, Takaki H, Fukui-Miyazaki A, Yoshida S, Matsumoto M, Seya T.

Biochem Biophys Res Commun. 2018 Dec 2;506(4):1019-1025. doi: 10.1016/j.bbrc.2018.10.166. Epub 2018 Nov 4.

5.

Extracellular RNA Sensing by Pattern Recognition Receptors.

Tatematsu M, Funami K, Seya T, Matsumoto M.

J Innate Immun. 2018;10(5-6):398-406. doi: 10.1159/000494034. Epub 2018 Nov 7. Review.

6.

Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants.

Takaki H, Ichimiya S, Matsumoto M, Seya T.

J Innate Immun. 2018;10(5-6):515-521. doi: 10.1159/000489405. Epub 2018 Jun 1. Review.

7.

The second and third amino acids of Pam2 lipopeptides are key for the proliferation of cytotoxic T cells.

Takeda Y, Azuma M, Hatsugai R, Fujimoto Y, Hashimoto M, Fukase K, Matsumoto M, Seya T.

Innate Immun. 2018 Jul;24(5):323-331. doi: 10.1177/1753425918777598. Epub 2018 May 31.

PMID:
29848176
8.

Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.

Takeda Y, Yoshida S, Takashima K, Ishii-Mugikura N, Shime H, Seya T, Matsumoto M.

Cancer Sci. 2018 Jul;109(7):2119-2129. doi: 10.1111/cas.13649. Epub 2018 Jun 16.

9.

TICAM-1 is dispensable in STING-mediated innate immune responses in myeloid immune cells.

Takashima K, Oshiumi H, Matsumoto M, Seya T.

Biochem Biophys Res Commun. 2018 May 23;499(4):985-991. doi: 10.1016/j.bbrc.2018.04.035. Epub 2018 Apr 9.

PMID:
29627569
10.

Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.

Takeda Y, Azuma M, Funami K, Shime H, Matsumoto M, Seya T.

Front Immunol. 2018 Mar 14;9:496. doi: 10.3389/fimmu.2018.00496. eCollection 2018.

11.

Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.

Seya T, Takeda Y, Takashima K, Yoshida S, Azuma M, Matsumoto M.

Proc Jpn Acad Ser B Phys Biol Sci. 2018;94(3):153-160. doi: 10.2183/pjab.94.011. Review.

12.

Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome.

Nakamura H, Oku K, Ogata Y, Ohmura K, Yoshida Y, Kitano E, Fujieda Y, Kato M, Bohgaki T, Amengual O, Yasuda S, Fujimura Y, Seya T, Atsumi T.

Thromb Res. 2018 Apr;164:63-68. doi: 10.1016/j.thromres.2018.02.142. Epub 2018 Feb 21.

PMID:
29494857
13.

Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model.

Yoshida S, Shime H, Takeda Y, Nam JM, Takashima K, Matsumoto M, Shirato H, Kasahara M, Seya T.

Cancer Sci. 2018 Apr;109(4):956-965. doi: 10.1111/cas.13543. Epub 2018 Mar 25.

14.

Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.

Matsumoto M, Takeda Y, Tatematsu M, Seya T.

Front Immunol. 2017 Dec 21;8:1897. doi: 10.3389/fimmu.2017.01897. eCollection 2017. Review.

15.

Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells.

Shime H, Maruyama A, Yoshida S, Takeda Y, Matsumoto M, Seya T.

Oncoimmunology. 2017 Sep 21;7(1):e1373231. doi: 10.1080/2162402X.2017.1373231. eCollection 2017.

16.

cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue.

Takaki H, Takashima K, Oshiumi H, Ainai A, Suzuki T, Hasegawa H, Matsumoto M, Seya T.

Med Sci (Basel). 2017 Dec 18;5(4). pii: E35. doi: 10.3390/medsci5040035.

17.

DNAJB1/HSP40 Suppresses Melanoma Differentiation-Associated Gene 5-Mitochondrial Antiviral Signaling Protein Function in Conjunction with HSP70.

Takashima K, Oshiumi H, Matsumoto M, Seya T.

J Innate Immun. 2018;10(1):44-55. doi: 10.1159/000480740. Epub 2017 Oct 26.

18.

The TLR3/TICAM-1 signal constitutively controls spontaneous polyposis through suppression of c-Myc in Apc Min/+ mice.

Ono J, Shime H, Takaki H, Takashima K, Funami K, Yoshida S, Takeda Y, Matsumoto M, Kasahara M, Seya T.

J Biomed Sci. 2017 Oct 17;24(1):79. doi: 10.1186/s12929-017-0387-z.

19.

Zyxin stabilizes RIG-I and MAVS interactions and promotes type I interferon response.

Kouwaki T, Okamoto M, Tsukamoto H, Fukushima Y, Matsumoto M, Seya T, Oshiumi H.

Sci Rep. 2017 Sep 19;7(1):11905. doi: 10.1038/s41598-017-12224-7.

20.

Functional interfaces between TICAM-2/TRAM and TICAM-1/TRIF in TLR4 signaling.

Funami K, Matsumoto M, Oshiumi H, Inagaki F, Seya T.

Biochem Soc Trans. 2017 Aug 15;45(4):929-935. doi: 10.1042/BST20160259. Epub 2017 Jun 19. Review.

PMID:
28630139
21.

Toll-like receptor 3 in nasal CD103+ dendritic cells is involved in immunoglobulin A production.

Takaki H, Kure S, Oshiumi H, Sakoda Y, Suzuki T, Ainai A, Hasegawa H, Matsumoto M, Seya T.

Mucosal Immunol. 2018 Jan;11(1):82-96. doi: 10.1038/mi.2017.48. Epub 2017 Jun 15.

PMID:
28612840
22.

Recognition of Viral RNA by Pattern Recognition Receptors in the Induction of Innate Immunity and Excessive Inflammation During Respiratory Viral Infections.

Okamoto M, Tsukamoto H, Kouwaki T, Seya T, Oshiumi H.

Viral Immunol. 2017 Jul/Aug;30(6):408-420. doi: 10.1089/vim.2016.0178. Epub 2017 Jun 13. Review.

PMID:
28609250
23.

A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.

Takeda Y, Kataoka K, Yamagishi J, Ogawa S, Seya T, Matsumoto M.

Cell Rep. 2017 May 30;19(9):1874-1887. doi: 10.1016/j.celrep.2017.05.015.

24.

Development of mouse models for analysis of human virus infections.

Takaki H, Oshiumi H, Shingai M, Matsumoto M, Seya T.

Microbiol Immunol. 2017 Apr;61(3-4):107-113. doi: 10.1111/1348-0421.12477. Review.

25.

The Anti-Oxidant Ergothioneine Augments the Immunomodulatory Function of TLR Agonists by Direct Action on Macrophages.

Yoshida S, Shime H, Funami K, Takaki H, Matsumoto M, Kasahara M, Seya T.

PLoS One. 2017 Jan 23;12(1):e0169360. doi: 10.1371/journal.pone.0169360. eCollection 2017.

26.

HTLV-1 Tax Induces Formation of the Active Macromolecular IKK Complex by Generating Lys63- and Met1-Linked Hybrid Polyubiquitin Chains.

Shibata Y, Tokunaga F, Goto E, Komatsu G, Gohda J, Saeki Y, Tanaka K, Takahashi H, Sawasaki T, Inoue S, Oshiumi H, Seya T, Nakano H, Tanaka Y, Iwai K, Inoue JI.

PLoS Pathog. 2017 Jan 19;13(1):e1006162. doi: 10.1371/journal.ppat.1006162. eCollection 2017 Jan.

27.

Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway.

Shime H, Matsumoto M, Seya T.

Cell Death Differ. 2017 Mar;24(3):385-396. doi: 10.1038/cdd.2016.131. Epub 2016 Nov 11.

28.

Extracellular Vesicles Including Exosomes Regulate Innate Immune Responses to Hepatitis B Virus Infection.

Kouwaki T, Fukushima Y, Daito T, Sanada T, Yamamoto N, Mifsud EJ, Leong CR, Tsukiyama-Kohara K, Kohara M, Matsumoto M, Seya T, Oshiumi H.

Front Immunol. 2016 Aug 31;7:335. doi: 10.3389/fimmu.2016.00335. eCollection 2016.

29.

Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo.

Leong CR, Funami K, Oshiumi H, Mengao D, Takaki H, Matsumoto M, Aly HH, Watashi K, Chayama K, Seya T.

Oncotarget. 2016 Oct 18;7(42):68179-68193. doi: 10.18632/oncotarget.11907.

30.

Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.

Azuma M, Takeda Y, Nakajima H, Sugiyama H, Ebihara T, Oshiumi H, Matsumoto M, Seya T.

Oncoimmunology. 2016 May 19;5(8):e1188244. doi: 10.1080/2162402X.2016.1188244. eCollection 2016 Aug.

31.

Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.

Takeda Y, Azuma M, Matsumoto M, Seya T.

J Exp Clin Cancer Res. 2016 Sep 13;35(1):143. doi: 10.1186/s13046-016-0416-x.

32.

STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation.

Takashima K, Takeda Y, Oshiumi H, Shime H, Okabe M, Ikawa M, Matsumoto M, Seya T.

Biochem Biophys Res Commun. 2016 Sep 30;478(4):1764-71. doi: 10.1016/j.bbrc.2016.09.021. Epub 2016 Sep 5.

PMID:
27608599
33.

The dataset of proteins specifically interacted with activated TICAM-1.

Funami K, Matsumoto M, Oshiumi H, Obuse C, Seya T.

Data Brief. 2016 Jun 28;8:697-9. doi: 10.1016/j.dib.2016.06.030. eCollection 2016 Sep.

34.

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.

Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S.

Nature. 2016 Jun 16;534(7607):402-6. doi: 10.1038/nature18294. Epub 2016 May 23.

PMID:
27281199
35.

Accessory Factors of Cytoplasmic Viral RNA Sensors Required for Antiviral Innate Immune Response.

Oshiumi H, Kouwaki T, Seya T.

Front Immunol. 2016 May 25;7:200. doi: 10.3389/fimmu.2016.00200. eCollection 2016. Review.

36.

Cytokine responses to eye spray adjuvants for enhancing vaccine-induced immunity in chickens.

Takaki H, Sato H, Kurata R, Hikono H, Hiono T, Kida H, Matsumoto M, Saito T, Seya T.

Microbiol Immunol. 2016 Jul;60(7):511-5. doi: 10.1111/1348-0421.12391.

37.

Double-stranded RNA analog and type I interferon regulate expression of Trem paired receptors in murine myeloid cells.

Kasamatsu J, Deng M, Azuma M, Funami K, Shime H, Oshiumi H, Matsumoto M, Kasahara M, Seya T.

BMC Immunol. 2016 May 3;17(1):9. doi: 10.1186/s12865-016-0147-y.

38.

14-3-3-zeta participates in TLR3-mediated TICAM-1 signal-platform formation.

Funami K, Matsumoto M, Obuse C, Seya T.

Mol Immunol. 2016 May;73:60-8. doi: 10.1016/j.molimm.2016.03.010. Epub 2016 Apr 6.

PMID:
27058640
39.

Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia.

Seya T, Takeda Y, Matsumoto M.

Oncoimmunology. 2015 Dec 8;5(2):e1043506. eCollection 2016 Feb.

40.

Raftlin Controls Lipopolysaccharide-Induced TLR4 Internalization and TICAM-1 Signaling in a Cell Type-Specific Manner.

Tatematsu M, Yoshida R, Morioka Y, Ishii N, Funami K, Watanabe A, Saeki K, Seya T, Matsumoto M.

J Immunol. 2016 May 1;196(9):3865-76. doi: 10.4049/jimmunol.1501734. Epub 2016 Mar 28.

41.

Live imaging of transforming growth factor-β activated kinase 1 activation in Lewis lung carcinoma 3LL cells implanted into syngeneic mice and treated with polyinosinic:polycytidylic acid.

Takaoka S, Kamioka Y, Takakura K, Baba A, Shime H, Seya T, Matsuda M.

Cancer Sci. 2016 May;107(5):644-52. doi: 10.1111/cas.12923. Epub 2016 Apr 27.

42.

[Nucleic acid pattern recognition for innate sensing of hepatitis B virus (HBV)].

Seya T, Funami K, Matsumoto M, Oshiumi H.

Nihon Rinsho. 2015 Dec;73 Suppl 9:392-6. Japanese. No abstract available.

PMID:
26845965
43.

Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage.

Takaki H, Shime H, Matsumoto M, Seya T.

Oncoimmunology. 2015 Dec 8;6(10):e1078968. doi: 10.1080/2162402X.2015.1078968. eCollection 2017.

44.

Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV).

Nakai M, Oshiumi H, Funami K, Okamoto M, Matsumoto M, Seya T, Sakamoto N.

Sensors (Basel). 2015 Oct 23;15(10):27160-73. doi: 10.3390/s151027160. Review.

45.

LRRC59 Regulates Trafficking of Nucleic Acid-Sensing TLRs from the Endoplasmic Reticulum via Association with UNC93B1.

Tatematsu M, Funami K, Ishii N, Seya T, Obuse C, Matsumoto M.

J Immunol. 2015 Nov 15;195(10):4933-42. doi: 10.4049/jimmunol.1501305. Epub 2015 Oct 14.

46.

RIOK3 keeps MDA5 inactive.

Takashima K, Oshiumi H, Seya T.

Oncotarget. 2015 Oct 13;6(31):30423-4. doi: 10.18632/oncotarget.5265. No abstract available.

47.

Identification of a Regulatory Acidic Motif as the Determinant of Membrane Localization of TICAM-2.

Funami K, Matsumoto M, Enokizono Y, Ishii N, Tatematsu M, Oshiumi H, Inagaki F, Seya T.

J Immunol. 2015 Nov 1;195(9):4456-65. doi: 10.4049/jimmunol.1402628. Epub 2015 Sep 25.

48.

Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.

Seya T, Shime H, Takeda Y, Tatematsu M, Takashima K, Matsumoto M.

Cancer Sci. 2015 Dec;106(12):1659-68. doi: 10.1111/cas.12824. Epub 2015 Nov 18. Review.

49.

Evolution of the DEAD box helicase family in chicken: chickens have no DHX9 ortholog.

Sato H, Oshiumi H, Takaki H, Hikono H, Seya T.

Microbiol Immunol. 2015 Oct;59(10):633-40. doi: 10.1111/1348-0421.12322.

50.

Electrical Retrieval of Living Microorganisms from Cryopreserved Marine Sponges Using a Potential-Controlled Electrode.

Koyama S, Nishi S, Tokuda M, Uemura M, Ishikawa Y, Seya T, Chow S, Ise Y, Hatada Y, Fujiwara Y, Tsubouchi T.

Mar Biotechnol (NY). 2015 Oct;17(5):678-92. doi: 10.1007/s10126-015-9651-y. Epub 2015 Aug 5.

Supplemental Content

Support Center